



Cancer mortality risk, fine particulate air pollution, and smoking in a large, representative cohort of US adults

Nathan C. Coleman¹ · Richard T. Burnett² · Joshua D. Higbee³ · Jacob S. Lefler⁴ · Ray M. Merrill⁵ · Majid Ezzati⁶ · Julian D. Marshall⁷ · Sun-Young Kim⁸ · Matthew Bechle⁷ · Allen L. Robinson⁹ · C. Arden Pope III¹

Received: 10 January 2020 / Accepted: 18 May 2020 / Published online: 27 May 2020
© Springer Nature Switzerland AG 2020

Abstract

Purpose Air pollution and smoking are associated with various types of mortality, including cancer. The current study utilizes a publicly accessible, nationally representative cohort to explore relationships between fine particulate matter (PM_{2.5}) exposure, smoking, and cancer mortality.

Methods National Health Interview Survey and mortality follow-up data were combined to create a study population of 635,539 individuals surveyed from 1987 to 2014. A sub-cohort of 341,665 never-smokers from the full cohort was also created. Individuals were assigned modeled PM_{2.5} exposure based on average exposure from 1999 to 2015 at residential census tract. Cox Proportional Hazard models were utilized to estimate hazard ratios for cancer-specific mortality controlling for age, sex, race, smoking status, body mass, income, education, marital status, rural versus urban, region, and survey year.

Results The risk of all cancer mortality was adversely associated with PM_{2.5} (per 10 µg/m³ increase) in the full cohort (hazard ratio [HR] 1.15, 95% confidence interval [CI] 1.08–1.22) and the never-smokers' cohort (HR 1.19, 95% CI 1.06–1.33). PM_{2.5}-mortality associations were observed specifically for lung, stomach, colorectal, liver, breast, cervix, and bladder, as well as Hodgkin lymphoma, non-Hodgkin lymphoma, and leukemia. The PM_{2.5}-mortality association with lung cancer in never-smokers was statistically significant adjusting for multiple comparisons. Cigarette smoking was statistically associated with mortality for many cancer types.

Conclusions Exposure to PM_{2.5} air pollution contributes to lung cancer mortality and may be a risk factor for other cancer types. Cigarette smoking has a larger impact on cancer mortality than PM_{2.5}, but is associated with similar cancer types.

Keywords PM_{2.5} · Cancer · Mortality · Air pollution · Smoking

✉ C. Arden Pope III
cap3@byu.edu

¹ Department of Economics, Brigham Young University, 142
FOB, Provo, UT 84602, USA

² Health Canada, Ottawa, ON, Canada

³ Department of Economics, University of Chicago, Chicago,
IL, USA

⁴ Department of Agricultural and Resource Economics,
University of California, Berkeley, CA, USA

⁵ Department of Public Health, Brigham Young University,
Provo, UT, USA

⁶ MRC-PHE Centre for Environment and Health, School
of Public Health, Imperial College, London, London, UK

⁷ Department of Civil and Environmental Engineering,
University of Washington, Seattle, WA, USA

⁸ Department of Cancer Control and Population Health,
Graduate School of Cancer Science and Policy, National
Cancer Center, Goyang-si, Gyeonggi-do, Korea

⁹ Engineering and Public Policy, Carnegie Mellon University,
Pittsburgh, PA, USA

Introduction

It is well established that inhalation of cigarette smoke substantially contributes to cardiopulmonary disease and the development of lung cancer [1]. In addition to lung cancer, evidence suggests that cigarette smoke likely contributes to the development of oral and oropharyngeal, esophageal, stomach, colorectal, liver, pancreatic, laryngeal, cervical, bladder, kidney cancer, as well as leukemia [1]. Although the effect estimates are much smaller, evidence suggests that cancer may also be associated with exposures to combustion-related fine particulate matter air pollution (PM_{2.5}, particles ≤ 2.5 μm in aerodynamic diameter).

There is evidence that PM_{2.5} air pollution contributes to chronic systemic inflammation [2], oxidative stress [3], and DNA damage [4]. Multiple studies have demonstrated that PM_{2.5} exposures are associated with cardiopulmonary disease mortality [5] as well as lung cancer incidence [6, 7] and mortality [6, 8, 9]. There is limited evidence that PM_{2.5} exposures are associated with incidence of various non-lung cancers including oral and oropharyngeal [10, 11], esophageal [11], stomach [11], liver [12], laryngeal [11], breast [13], bladder [14], kidney cancer [15], and leukemia [16]. PM_{2.5} exposures are also associated with mortality from stomach [17, 18], colorectal [17–19], liver [20], pancreatic [21], breast [18, 22], female organ [18], bladder [19, 23], kidney cancer [19], and leukemia [16]. Unfortunately, these studies are limited in scope and number and not fully consistent in their findings.

The primary objective of the current study is to evaluate PM_{2.5}-mortality associations with specific cancer types among a large, nationally representative cohort of adults residing in the USA. Secondary objectives of this study are to use the same cohort and statistical models to evaluate associations between cigarette smoking and mortality for specific cancer types and to compare these associations with those observed with PM_{2.5} air pollution.

Methods

Study subjects

Public National Health Interview Survey (NHIS) and National Death Index data were used to construct a cohort of individuals aged 18–84 at the time of survey, living in the continental US, and completed the NHIS survey between 1987 and 2014 as documented elsewhere [5]. Participants represented the civilian non-institutionalized US adult population. Participant responses were linked to

the National Death Index for mortality follow-up through 2015. In addition, restricted-use geographic data allowed for the assignment of ambient pollution estimates at the census tract level. Analyses were performed on two cohorts. The first cohort consisted of the 635,539 individuals (age range 18–84 years, mean age 45.3) and the second was a subset of this group of 341,665 participants who self-reported as never-smokers (age range 18–84, mean age 43.4). Both cohorts contained information on age, sex, race-ethnicity (Non-Hispanic white, Hispanic, Non-Hispanic black, or other), income buckets (\$0–35,000, \$35,000–50,000, \$50,000–75,000, or over \$75,000), marital status (married, divorced, separated, never married, or widowed), educational attainment (less than high school grad, high school grad, some college, college grad, more than college grad), BMI, smoking status (self-identified as current, former, or never-smoker), census tract, ambient pollution exposure, interview date, date of death, and underlying cause of death (if deceased). Further information about the composition of the cohorts, including details regarding the merging and harmonization of key variables, is provided elsewhere [5]. Procedures for informed consent, data collection, and linkage of the NHIS files were approved by the NCHS Ethics Review Board. Findings and conclusions of this research are those of the authors and do not necessarily represent the views of the RDC, the NCHS, the Environmental Protection Agency, or the Centers for Disease Control and Prevention.

Pollution concentration

In the baseline analysis, each study subject was assigned pollution exposure based on estimated modeled population-weighted average concentrations of PM_{2.5} at their resident census tract, averaged across the 17-year period from 1999 through 2015. Individuals surveyed from 1987 to 2010 were linked to census tract-level estimates of PM_{2.5} using census tracts of the year 2000, while individuals surveyed from 2011 to 2014 were linked using census tracts of the year 2010. Because many individuals were surveyed before 1999, and in order to explore an alternative longer window of pollution exposure, average PM_{2.5} for a 28-year exposure period from 1988 to 2015 was estimated using back casted PM_{2.5} estimates from 1988 to 1998. Back casted estimates for PM_{2.5} from 1988 to 1998 relied on the fact that PM_{2.5} is a primary component of PM₁₀ and PM_{2.5} and PM₁₀ concentrations were highly correlated during the period when they were co-monitored and before there was a more focused effort to reduce PM_{2.5} (approximately 1999–2003). Specifically, the back casted estimates were computed by calculating mean PM_{2.5}/PM₁₀ ratios for 1999–2003 for each census tract and then multiplying the PM₁₀ estimate for each census tract from 1988–1998 as documented in detail elsewhere

[5]. Estimated average $PM_{2.5}$ concentrations for the primary 17-year period (1999–2015) were highly correlated ($r > 0.95$) with the estimated $PM_{2.5}$ concentrations for the 28-year (1988–2015) period that included the additional back casted data. Documentation of air pollution estimates utilized in this study is located elsewhere [24]. The modeled air pollution data are publicly accessible at the Center for Air, Climate, & Energy Solutions website (<https://www.caces.us/>).

Statistical methods

Hazards ratios and 95% confidence intervals for cancer mortality risk associated with a $10 \mu\text{g}/\text{m}^3$ increase in $PM_{2.5}$ concentrations were estimated using Cox Proportional Hazards (CPH) models that accounted for the complex, stratified, multistage NHIS sample design [25]. Estimates were computed using the SURVEYPHREG procedure in SAS version 9.3 (SAS Institute, Cary, North Carolina). Models were estimated for specific causes of death. Survival times were calculated using the date of interview as the beginning of follow-up. For those who died of the specific cause of death under analysis, the end of follow-up was date of death for that specific cause of death. For those who died of any other cause of death, censored end of follow-up was date of death. For survivors, the censored end of follow-up was the end of mortality follow-up (31 December 2015). All models were adjusted for age-sex-race interactions (using indicators for 5-year age buckets) and categorical variables for BMI, income, education, marital status, rural versus urban, region, and survey year. In the full cohort, models were also adjusted for smoking status. Hazards ratios and 95% confidence intervals for cancer-type-specific mortality risk associated with smoking status were also estimated. To account for multiple testing, adaptive Holms adjusted p values [26] were calculated.

The specific cancer types analyzed in this analysis are based on ICD-10 Underlying Cause of Death (including recodes for 1979–2015) as documented elsewhere [27]. Specific causes of cancer mortality included ICD-10 codes for lung (C33–C34), oral and oropharyngeal (C00–C14), esophageal (C15), stomach (C16), colorectal (C18–C21), liver (C22), pancreatic (C25), laryngeal (C32), melanoma (C43), breast (C50), cervical (C53), ovarian (C54–C55), uterine (C56), prostate (C61), kidney (C64–C65), bladder (C67), and brain cancer (C70–C72) as well as Hodgkin lymphoma (C81), non-Hodgkin lymphoma (NHL) (C82–C85), leukemia (C91–C95), multiple myeloma (C88, C90), and other unspecified cancers (C17, C23–24, C26–C49, C51–52, C57–60, C62–63, C66, C68–C69, C73–C80, C97).

To explore model sensitivity, the results from the original complex CPH model, as described above, were compared with results from alternative models using the traditional

Cox Proportional Hazards model (the PHREG procedure). Alternative models included: Model 1 that included mean $PM_{2.5}$ concentrations for the 17-year period (1999–2015) and controlled for covariates as in the original model (education, income, marital status, BMI, smoking status, urban/rural, census region, and survey year), but controlled for combinations of 1-year age groups, sex and race-ethnicity by allowing them to have their own baseline hazard (using the STRATA statement in the SAS PHREG procedure). Model 2 is the same as Model 1 but includes only individual controls and excludes survey year, census region, and urban/rural variables. Model 3 is the same as Model 1 but only controlled for age, sex, and race-ethnicity (using the STRATA statement). Model 4 is the same as Model 1, except it used the longer exposure window for $PM_{2.5}$ (average exposure from 1988 to 2015 instead of 1999 to 2015, using back casted estimates for 1988–1998). Model 5 is the same as Model 1, but only included individuals surveyed during or after 1999. Model 6 is the same as Model 1 except it used an expanded cohort of all 1,599,329 NHIS participants from 1986 to 2014 (including individuals without smoking status or BMI data) and did not control for smoking status or BMI.

Results

Table 1 presents summary statistics for both the full and never-smokers' cohort groups. Individual mean estimated ambient $PM_{2.5}$ exposure was $10.7 \mu\text{g}/\text{m}^3$ (standard deviation 2.4) in both the full cohort and never-smokers' cohort. The table also contains the average estimated $PM_{2.5}$ exposure for the levels of the selected variables. Individual mean exposure is relatively consistent across varying factor levels aside from race/ethnicity (greater in non-Hispanic Blacks), urban versus rural (greater in urban areas), and census region (greater in the Midwest).

Table 2 provides cancer-type-specific mortality hazard ratios (HRs) and 95% confidence intervals (CIs) associated with $10 \mu\text{g}/\text{m}^3$ increased $PM_{2.5}$ exposure in both the full and never-smokers' cohorts. Statistically significant associations were observed in the full cohort for lung, stomach, colorectal, breast, cervical, and bladder cancer, as well as Hodgkin's lymphoma, NHL, and leukemia. However, after adjusting for multiple comparisons, these associations were not statistically significant. In the never-smokers' cohort, statistically significant associations between $PM_{2.5}$ and mortality were found for lung, stomach, liver, breast, and cervical cancers as well as Hodgkin lymphoma. Only lung cancer was statistically significant after adjusting for multiple comparisons. Table 3 shows sensitivity analysis performed on the full cohort for lung, stomach, colorectal, liver, cervical, breast, and bladder cancers as well as Hodgkin's lymphoma, NHL, and leukemia. The $PM_{2.5}$ -mortality associations across the

Table 1 Summary of baseline characteristics in the full and never-smoker's cohort for individuals aged 18–84 who completed the US National Health Interview Survey between 1987 and 2014

Variable	Full cohort (No. = 635,539)		Never-smokers' cohort (No. = 341,665)	
	%	Mean (SD) PM _{2.5}	%	Mean (SD) PM _{2.5}
Sex				
Male	44.5	10.7 (2.4)	38.6	10.7 (2.4)
Female	55.5	10.6 (2.4)	61.4	10.8 (2.4)
Race/ethnicity				
Non-Hispanic White	67.5	10.3 (2.2)	61.4	10.3 (2.2)
Hispanic	14.1	11.2 (3.0)	17.6	11.3 (3.0)
Non-Hispanic Black	14.0	11.7 (1.9)	15.4	11.7 (1.9)
All other/unknown	4.4	11.0 (2.6)	5.6	11.1 (2.6)
Income (inflation adjusted to 2015)				
\$0–35,000	38.0	10.8 (2.4)	36.6	10.9 (2.4)
\$35–50,000	15.5	10.6 (2.4)	14.9	10.7 (2.4)
\$50–75,000	18.8	10.6 (2.4)	18.7	10.7 (2.4)
\$75,000+	27.7	10.5 (2.3)	29.9	10.6 (2.3)
Marital status				
Married	49.6	10.5 (2.4)	49.9	10.6 (2.4)
Divorced	14.1	10.6 (2.4)	10.9	10.7 (2.4)
Separated	3.6	11.1 (2.4)	3.1	11.2 (2.4)
Never married	24.3	11.0 (2.3)	27.8	11.0 (2.4)
Widowed	8.5	10.7 (2.3)	8.3	10.8 (2.3)
Education				
< High school grad	18.6	11.1 (2.5)	16.8	11.2 (2.5)
High school grad	30.4	10.6 (2.3)	27.1	10.7 (2.4)
Some college	27.1	10.5 (2.4)	27.2	10.6 (2.3)
College grad	15.0	10.6 (2.3)	18.1	10.6 (2.3)
> College grad	8.9	10.6 (2.3)	10.9	10.6 (2.3)
Urban/rural				
Urban	77.6	11.0 (2.4)	79.4	11.0 (2.4)
Rural	22.4	9.6 (2.1)	20.6	9.6 (2.1)
Census region				
Northeast	18.1	10.6 (1.9)	17.5	10.8 (1.9)
Midwest	23.7	11.1 (1.7)	22.5	11.1 (1.9)
South	35.7	10.8 (1.7)	36.3	10.8 (1.7)
West	22.5	10.0 (3.6)	23.8	10.3 (3.7)
BMI				
< 20	7.3	10.7 (2.3)	7.3	10.7 (2.3)
20–25	36.4	10.6 (2.4)	36.7	10.7 (2.4)
25–30	33.8	10.7 (2.4)	33.1	10.7 (2.4)
30–35	14.4	10.7 (2.4)	14.5	10.8 (2.4)
> 35	8.1	10.8 (2.3)	8.4	10.8 (2.3)
Smoking				

Table 1 (continued)

Variable	Full cohort (No. = 635,539)		Never-smokers' cohort (No. = 341,665)	
	%	Mean (SD) PM _{2.5}	%	Mean (SD) PM _{2.5}
Never	53.8	10.7 (2.4)	100.0	10.7 (2.4)
Current	23.9	10.7 (2.3)	0.0	–
Former	22.4	10.5 (2.4)	0.0	–

different cancer types were reasonably insensitive to various modeling choices, different exposure windows, and using the expanded NHIS cohort.

Table 4 provides HRs and 95% CIs associated with identifying a patient as a current smoker or former smoker and cancer-type-specific mortality in the full cohort. Statistically significant smoking-cancer mortality HRs for current smokers were found for lung, oral and oropharyngeal, esophageal, stomach, colorectal, liver, pancreatic, cervical, prostate, kidney, bladder, laryngeal, brain, and unspecified cancers as well as leukemia. For former smokers, statistically significant associations were found for lung, oral and oropharyngeal, esophageal, colorectal, liver, breast, bladder, laryngeal, and unspecified cancers as well as NHL and leukemia. After adjustment for multiple comparison, statistically significant associations were found for lung, oral and oropharyngeal, esophageal, stomach, colorectal, liver, pancreatic, cervical, bladder, laryngeal, and unspecified cancers in current smokers and lung, oral and oropharyngeal, esophageal, colorectal, liver, bladder, laryngeal, and unspecified cancers in former smokers.

Discussion

Consistent with a growing body of literature, this study provides evidence that cancer mortality is associated with PM_{2.5} exposure in both smokers and never-smokers. Analysis of the full cohort resulted in a hazard ratio of 1.15 (95% confidence interval of 1.08–1.22), which was comparable to that of the never-smokers' cohort (HR 1.19, 95% CI 1.06–1.33). The result was comparable to a cohort that used 18.9 million Medicare beneficiaries. The estimated HR per 10 µg/m³ increase of PM_{2.5} was 1.11 (95% CI 1.09–1.12) [28]. Analysis of the full cohort for non-lung cancers resulted in a hazard ratio of 1.15 (95% CI 1.07–1.24) which was also comparable to the cohort of never-smokers' (HR 1.15, 95% CI 1.02–1.30). The results for the association between a 10 µg/m³ increase of PM_{2.5} and non-lung cancer are much larger than other cohort studies like the Harvard Six Cities Study (HR 1.05, 95% CI 0.87–1.27) [29] or the ACS study (HR 1.05, 95% CI 1.00–1.12) [29], but not statistically different.

Table 2 Estimated hazard ratios (95% CIs) associated with 10 $\mu\text{g}/\text{m}^3$ increase of $\text{PM}_{2.5}$ adjusted for age, sex, race/ethnicity, income, education, marital status, BMI, smoking (for the full cohort), urban/rural, census regions, and survey year

Cancer types	Full cohort			Never-smokers' cohort		
	No. of deaths	Hazard ratio (95% CI)	Holm's <i>p</i> value	No. of deaths	Hazard ratio (95% CI)	Holm's <i>p</i> value
<i>All cancer</i>	26,453	1.15 (1.08–1.22)*	–	17,743	1.19 (1.06–1.33)*	–
Lung	7,420	1.13 (1.00–1.26)*	0.58	6,710	1.73 (1.20–2.49)* [†]	0.04
Non-lung	19,033	1.15 (1.07–1.24)*	–	11,033	1.15 (1.02–1.30)*	–
<i>Digestive and accessory</i>						
Oral and oropharyngeal	374	1.19 (0.74–1.91)	1	291	1.90 (0.65–5.54)	1
Esophageal	599	0.59 (0.38–0.90)	0.19	460	0.79 (0.32–1.96)	1
Stomach	525	1.87 (1.20–2.92)*	0.07	301	2.01 (1.01–3.98)*	0.51
Colorectal	2,572	1.29 (1.05–1.58)*	0.18	1,441	1.26 (0.93–1.70)	1
Liver	761	1.32 (0.94–1.85)	1	489	2.18 (1.25–3.81)*	0.06
Pancreas	1,607	1.09 (0.83–1.44)	1	956	0.94 (0.63–1.38)	1
<i>Sex specific organs</i>						
Breast	2,099	1.33 (1.08–1.64)*	0.09	949	1.32 (1.00–1.75)*	0.60
Cervical	237	1.77 (1.00–3.16)*	0.62	115	2.41 (1.19–4.89)*	0.17
Ovarian	392	1.03 (0.69–1.53)	1	121	1.06 (0.60–1.86)	1
Uterine	750	1.20 (0.73–1.96)	1	317	1.64 (0.94–2.88)	0.91
Prostate	1,215	0.91 (0.68–1.22)	1	802	0.60 (0.39–0.93)	0.26
<i>Urinary</i>						
Kidney	603	0.98 (0.66–1.46)	1	359	0.94 (0.48–1.84)	1
Bladder	589	1.48 (1.00–2.20)*	0.63	451	2.00 (0.83–4.84)	1
<i>Lymphoid</i>						
Hodgkin lymphoma	59	4.18 (1.20–14.60)*	0.30	31	6.21 (1.15–33.46)*	0.37
NHL	1,016	1.48 (1.10–1.98)*	0.11	558	1.27 (0.81–2.01)	1
Leukemia	970	1.43 (1.05–1.97)*	0.31	564	1.34 (0.76–2.33)	1
Multiple myeloma	541	0.99 (0.64–1.53)	1	270	0.83 (0.45–1.54)	1
<i>Other cancers</i>						
Laryngeal	157	0.82 (0.34–1.96)	1	142	0.74 (0.02–25.03)	1
Melanoma	392	0.72 (0.39–1.33)	1	213	0.54 (0.19–1.58)	1
Brain	622	1.48 (0.96–2.29)	0.89	344	1.51 (0.84–2.70)	1
Unspecified cancers	2,952	0.89 (0.74–1.07)	1	1,858	0.80 (0.60–1.07)	1

P values adjusted using the Holm's method are also included for individual cancer types. Note that a *p*-value of 1 indicates a value greater than 0.9999 as reported by SAS PROC MULTTEST

*Significant at 95% confidence level using the unadjusted *p*-values

[†] Significant at 95% confidence level using Holm's adjusted *p*-values

This study provides further evidence that lung cancer is associated with $\text{PM}_{2.5}$, especially in never-smokers. The study found a hazard ratio of 1.13 (95% CI 1.00–1.26) in the full cohort and a HR of 1.73 (95% CI 1.20–2.49) in the never-smokers' cohort, which was significant even after multiple comparison adjustment. The $\text{PM}_{2.5}$ -lung cancer mortality HR was higher in the never-smokers' cohort than in the full cohort. It is unknown whether or not the larger HR for never-smokers is due to different susceptibility, underlying biology, or simply due to differences in baseline risk. Given the large effect of smoking on lung cancer, the underlying or baseline mortality risk for lung cancer in never-smokers is much smaller than for smokers. As such the proportional

hazard (an estimate of relative risk) associated with $\text{PM}_{2.5}$ exposure would likely be larger in never-smokers than in smokers. The results from this study are comparable to a recent meta-analysis of cohorts examining $\text{PM}_{2.5}$ -lung cancer mortality (HR 1.13, 95% CI 1.07–1.20) [30].

The association between $\text{PM}_{2.5}$ and mortality due to non-lung cancers is less clear. Although several cancer types (stomach, colorectal, liver, breast, cervical, and bladder cancers and Hodgkin's lymphoma, NHL, and leukemia) were statistically significantly associated with $\text{PM}_{2.5}$ exposure, none were statistically significant after adjusting for multiple comparisons. However, despite the conservative *p* value adjustment, stomach, liver, and breast cancer had a Holm's

Table 3 Model sensitivity was performed by comparing the results from the original complex CPH model to several alternative models using the traditional Cox Proportional Hazards model (the PHREG procedure)

Cancer type	Original model (all controls)	Model 1 (all controls)	Model 2 (individual controls)	Model 3 (age, sex, race)	Model 4 (back casted PM _{2.5})	Model 5 (≥ 1999 survey years)	Model 6 (expanded)
Lung	1.13 (1.00–1.26)	1.12 (1.00–1.25)	1.14 (1.03–1.26)	1.22 (1.10–1.35)	1.10 (1.00–1.20)	1.16 (0.95–1.41)	1.09 (1.02–1.17)
Stomach	1.87 (1.20–2.92)	1.82 (1.24–2.69)	1.78 (1.22–2.58)	1.81 (1.24–2.63)	1.63 (1.20–2.22)	2.18 (1.10–4.33)	1.80 (1.45–2.24)
Colorectal	1.29 (1.05–1.58)	1.23 (1.02–1.47)	1.32 (1.11–1.57)	1.36 (1.14–1.61)	1.18 (1.02–1.36)	1.28 (0.92–1.77)	1.26 (1.12–1.41)
Liver	1.32 (0.94–1.85)	1.35 (0.99–1.84)	1.37 (1.01–1.85)	1.38 (1.02–1.87)	1.22 (0.95–1.56)	1.39 (0.89–2.17)	1.33 (1.10–1.60)
Cervix	1.78 (1.00–3.16)	2.22 (1.27–3.88)	2.18 (1.26–3.78)	2.45 (1.42–4.22)	1.69 (1.09–2.63)	2.04 (0.80–5.24)	1.71 (1.20–2.44)
Breast	1.33 (1.08–1.64)	1.26 (1.03–1.54)	1.28 (1.06–1.55)	1.28 (1.06–1.55)	1.22 (1.04–1.43)	1.38 (0.97–1.96)	1.28 (1.13–1.45)
Bladder	1.48 (1.00–2.20)	1.26 (0.86–1.84)	1.26 (0.88–1.80)	1.29 (0.90–1.84)	1.22 (0.91–1.65)	1.49 (0.80–2.78)	1.00 (0.79–1.27)
Hodgkin's	4.18 (1.19– 14.60)	3.22 (1.05–9.86)	3.45 (1.18– 10.08)	3.59 (1.22– 10.56)	2.33 (0.96–5.67)	11.27 (1.45– 87.79)	1.57 (0.78–3.14)
NHL	1.48 (1.10–1.98)	1.49 (1.12–1.98)	1.61 (1.22–2.11)	1.59 (1.21–2.08)	1.34 (1.07–1.68)	1.94 (1.18–3.18)	1.35 (1.14–1.61)
Leukemia	1.43 (1.05–1.97)	1.27 (0.94–1.71)	1.34 (1.01–1.77)	1.30 (0.98–1.72)	1.25 (0.99–1.58)	1.92 (1.17–3.15)	1.22 (1.02–1.46)

Model 1 included mean PM_{2.5} concentrations for the 17-year period (1999–2015) and controlled for covariates as in the original model (education, income, marital status, BMI, smoking status, urban/rural, census region, and survey year), but controlled for combinations of 1-year age groups, sex, and race-ethnicity by allowing them to have their own baseline hazard (using the STRATA statement in the SAS PHREG procedure). Model 2 is the same as Model 1, but includes only individual controls and excludes survey year, census region, and urban/rural variables. Model 3 is the same as Model 1, but only controlled for age, sex, and race (using the STRATA statement). Model 4 is the same as Model 1, except it is used a longer exposure window for PM_{2.5} (average exposure from 1988–2015 instead of 1999–2015, using back casted estimates for 1988–1998). Model 5 is the same as Model 1, but only included individuals surveyed during or after 1999. Model 6 is the same as Model 1, except it used an expanded cohort of all 1,599,329 NHIS participants from 1986–2014 (including individuals without smoking status or BMI data) and did not control for smoking status or BMI

p-value of less than 0.1, suggestive of an association with PM_{2.5}. Furthermore, the statistically significant association between non-lung cancers in aggregate and PM_{2.5} in both the full and never-smokers cohort provides further suggestive evidence that some non-lung cancers are associated with PM_{2.5}.

Other studies have reported PM_{2.5}-mortality associations with stomach [18, 19, 31], colorectal [18, 19, 31], liver [18–20, 31], breast [18, 19, 21, 32, 33], cervical [18, 19], and bladder cancer [18, 19]. Additional studies have also reported PM_{2.5}-incidence associations for stomach [11], liver [12, 34, 35], breast [13, 36–40], and bladder [14, 41]. Comparisons of the estimated hazard ratios, risk ratios, incident rate ratios, and odds ratios (with their associated confidence intervals) for these cancers are succinctly illustrated in Fig. 1. Although there is substantial heterogeneity across study estimates, the results of this study provide additional evidence to the growing body of literature that PM_{2.5} exposure is associated with cancer mortality or incidence for lung and some non-lung cancers.

The results are also consistent with existing literature on the relationship between smoking and cancer [1], with statistically significant associations after multiple testing adjustment for lung, oral and oropharyngeal, esophageal, stomach, colorectal, liver, pancreatic, laryngeal, cervical, kidney, bladder, and unspecified cancers. Except for Hodgkin's and non-Hodgkin's lymphoma, cancer types that were

statistically associated with PM_{2.5} in either cohort were also associated with smoking status. This study also provides moderate evidence for the formal establishment of prostate, breast, and unspecified cancers as caused by smoking [42]. Cigarette smoking and PM_{2.5} exposure may both be risk factors for various non-lung cancers, with cigarette smoking having a larger impact. Further research is needed to determine the relationship between PM_{2.5}, smoking, and cancer type mortality.

A limitation of this study is the inability to directly measure exposure to ambient air pollution over a lifetime. With extensive follow-up and advanced ground-based monitoring and related modeling, this study used direct exposure estimates from 1999 to 2015. However, it does not directly account for exposure before this period. Although the results using back casted estimates of PM_{2.5} exposure and only including individuals surveyed after 1999 are similar to the original model, the estimates of the HR may still be biased. Furthermore, census tract-level estimates of PM_{2.5} do not account for the full range of spatial variability at residential address. Due to subject mobility, however, it remains unclear what is the optimal level of spatial averaging. Another limitation is the inability to control for migration. The migration problem is further exacerbated by the long latency period of some cancer types. In future studies, cancer incidence data could be used to reduce the latency concern. Additionally, this study did not control for other pollutants such as NO₂,

Table 4 Estimated hazard ratios (95% CIs) associated with current or former smoker in comparison to never-smoker

Cancer types	Current smoker			Former smoker		
	No. of deaths	Hazard ratio (95% CI)	Holm's <i>p</i> value	No. of deaths	Hazard ratio (95% CI)	Holm's <i>p</i> value
<i>All cancer</i>	26,453	2.73 (2.64–2.83)*	–	26,453	1.48 (1.43–1.53)*	–
Lung	7,420	15.11 (13.70–16.66)* [†]	< 0.01	7,420	4.90 (4.44–5.42)* [†]	< 0.01
Non-lung	19,033	1.59 (1.53–1.66)*	–	19,033	1.18 (1.13–1.22)*	–
<i>Digestive and accessory</i>						
Oral and oropharyngeal	374	4.84 (3.65–6.42)* [†]	< 0.01	374	1.66 (1.21–2.27)* [†]	0.02
Esophageal	599	3.25 (2.58–4.10)* [†]	< 0.01	599	1.67 (1.32–2.12)* [†]	< 0.01
Stomach	525	1.74 (1.28–2.38)* [†]	< 0.01	525	1.15 (0.91–1.45)	1
Colorectal	2,572	1.37 (1.22–1.55)* [†]	< 0.01	2,572	1.23 (1.12–1.35)* [†]	< 0.01
Liver	761	2.09 (1.72–2.55)* [†]	< 0.01	761	1.45 (1.20–1.75)* [†]	< 0.01
Pancreas	1,607	2.04 (1.78–2.35)* [†]	< 0.01	1,607	1.14 (0.99–1.32)	0.74
<i>Sex specific organs</i>						
Breast	2,099	1.11 (0.99–1.26)	0.40	2,099	1.12 (1.00–1.27)*	0.62
Cervical	237	1.53 (1.13–2.09)* [†]	0.04	237	1.04 (0.70–1.53)	1
Ovarian	392	0.97 (0.79–1.18)	1	392	1.05 (0.87–1.27)	1
Uterine	750	0.68 (0.50–0.93)	0.02	750	0.65 (0.48–0.87)	0.20
Prostate	1,215	1.27 (1.05–1.54)*	0.09	1,215	0.99 (0.86–1.14)	1
<i>Urinary</i>						
Kidney	603	1.34 (1.06–1.69)*	0.09	603	1.10 (0.90–1.35)	1
Bladder	589	4.08 (3.20–5.20)* [†]	< 0.01	589	2.39 (1.89–3.01)* [†]	< 0.01
<i>Lymphoid</i>						
Hodgkin lymphoma	59	0.94 (0.45–1.96)	1	59	1.04 (0.51–2.09)	1
NHL	1,016	1.13 (0.93–1.37)	0.82	1,016	1.18 (1.01–1.38)*	0.48
Leukemia	970	1.23 (1.01–1.52)*	0.27	970	1.24 (1.04–1.47)*	0.19
Multiple myeloma	541	0.76 (0.58–0.99)	0.27	541	0.95 (0.76–1.18)	1
<i>Other cancers</i>						
Laryngeal	157	10.27 (5.44–19.38)* [†]	< 0.01	157	3.04 (1.46–6.33)* [†]	0.04
Melanoma	392	1.01 (0.76–1.33)	1	392	0.99 (0.77–1.28)	1
Brain	622	1.37 (1.07–1.74)*	0.07	622	1.03 (0.83–1.27)	1
Unspecified cancers	2,952	2.14 (1.93–2.38)* [†]	< 0.01	2,952	1.27 (1.16–1.39)* [†]	< 0.01

All models were adjusted for age, sex, race, income, education, marital status, BMI, urban/rural, census regions, survey year, and a 10 $\mu\text{g}/\text{m}^3$ increase of $\text{PM}_{2.5}$. P-values adjusted using the Holm's method are also included for individual cancer types. Note that a p-value of 1 indicates a value greater than 0.9999 as reported by SAS PROC MULTTEST

*Significant at 95% confidence level using the unadjusted p-values


[†]Significant at 95% confidence level using Holm's adjusted p-values

SO_2 , or CO. Other studies have found associations between pollutants other than $\text{PM}_{2.5}$ and incidence and mortality from various cancers [43, 44]. Future studies should control for these pollutants.

Another limitation of the study is the potential of residual confounding. The study was unable to control for several important variables such as secondhand smoke, HPV status, occupational exposure, reproductive factors (such as hormonal therapy, oral contraceptive use, or menopausal status), alcohol consumption, dietary patterns, and genetic variables that are associated with some cancer types. However, most cancer types were not sensitive to individual risk factors such as age, sex, race-ethnicity, education, income, BMI,

geographic variables, and survey years, which suggests negligible risk of residual confounding. Furthermore, average air pollution was generally consistent across the factor levels for the individual risk factors, which suggests air pollution is unlikely to be correlated with any omitted variables.

A final limitation is the lack of follow-up and quantitative measurements in the smoking data. The lack of follow-up would likely bias the estimates for smoking downwards because the number of smokers is decreasing in America. Future studies should also include quantitative measurements for smoking such as packs per day or number of years smoking. Although these weaknesses may call the results of the smoking analysis into question, many of the cancer



* The Wong et al 2016 study includes esophageal cancer in its evaluation of stomach cancer, pancreatic with liver cancer, ovarian and uterine with cervical cancer, and kidney with bladder cancer.

Fig. 1 Illustration of the comparison between the results of the current study and other similar studies that estimated the association between a 10 $\mu\text{g}/\text{m}^3$ increase of $\text{PM}_{2.5}$ and various cancer types

incidence or mortality. Studies that examined cancer incidence are marked with a triangle, whereas those that examined cancer mortality are marked with a circle

types that were associated with current smokers are also associated with former smokers, so the lack of follow-up and number of years smoked is less concerning. Furthermore, $\text{PM}_{2.5}$ -cancer associations were similar in the never-smokers' cohort, which suggests little risk of bias.

This study has several important strengths. First, the study uses a cohort that is a representative sample of US adults with high quality survey information. Second, the cohort is large and contains many deaths for most cancer types. Third, the analysis can control for individual risk factors for cancer

such as smoking and BMI. Fourth, air pollution estimates, and most other analysis variables are publicly available.

Exposure to PM_{2.5} air pollution is a risk factor for lung cancer mortality and a possible risk factor in mortality for various cancer types. The results from the current study and comparable studies suggest that PM_{2.5} may be associated with stomach, colorectal, liver, breast, cervical, and bladder cancer. Interestingly, all these cancers were associated with smoking status in the analysis. Although this exploratory study does not provide definitive conclusions, the strength of the research design and the consistency of results across modeling choices suggest further research is needed into the additional biological pathways by which cancer in humans may be affected by PM_{2.5} and smoking. The universal nature of pollution exposure, and its consequences, makes further study essential to public health.

Acknowledgments M.E. reports a charitable grant from AstraZeneca Young Health Programme, and personal fees from Prudential, Scor and Third Bridge, all outside the submitted work.

Funding This publication was developed as part of the Center for Air, Climate, and Energy Solutions (CACES), which was supported under Assistance Agreement No. R835873 awarded by the US Environmental Protection Agency. It has not been formally reviewed by EPA. The views expressed in this document are solely those of authors and do not necessarily reflect those of the Agency. EPA does not endorse any products or commercial services mentioned in this publication.

Compliance with ethical standards

Conflict of interest The authors declare no potential conflicts of interest.

References

1. U.S. Department of Health and Human Services (2014) The health consequences of smoking: 50 years of progress. a report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014. Printed with corrections, January 2014
2. Loomis D, Grosse Y, Lauby-Secretan B (2013) The carcinogenicity of outdoor air pollution. *Lancet Oncol* 14(13):1262–1263
3. Risom L, Møller P, Loft S (2005) Oxidative stress-induced DNA damage by particulate air pollution. *Mutat Res* 592(1):119–137
4. Newby DE, Mannucci PM, Tell GS et al (2014) Expert position paper on air pollution and cardiovascular disease. *Eur Heart J* 36(2):83–93
5. Pope CA III, Lefler JS, Ezzati M et al (2019) Mortality risk and fine particulate air pollution in a large, representative cohort of US adults. *Environ Health Persp* 127(7):077007
6. IARC (2013) Outdoor air pollution. IARC Monogr Eval Carcinog Risk Hum 109: 1. <https://monographs.iarc.fr/ENG/Monographs/vol109/mono109-F01.pdf>. Accessed 19 Mar 2016
7. Cui P, Huang Y, Han J, Song F, Chen K (2014) Ambient particulate matter and lung cancer incidence and mortality: a meta-analysis of prospective studies. *Eur J Public Health* 25(2):324–329
8. Turner MC, Krewski D, Pope CA III, Chen Y, Gapstur SM, Thun MJ (2011) Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers. *Am J Resp Crit Care* 184(12):1374–1381
9. Hamra GB, Guha N, Cohen A et al (2014) Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis. *Environ Health Persp*. <https://doi.org/10.1289/ehp/1408092>
10. Chu YH, Kao SW, Tantoh DM, Ko PC, Lan SJ, Liaw YP (2019) Association between fine particulate matter and oral cancer among Taiwanese men. *J Invest Med* 67(1):34–38
11. Nagel G, Stafoggia M, Pedersen M et al (2018) Air pollution and incidence of cancers of the stomach and the upper aerodigestive tract in the European Study of Cohorts for Air Pollution Effects (ESCAPE). *Int J Cancer*. <https://doi.org/10.1002/ijc.31564>
12. VoPham T, Bertrand KA, Tamimi RM, Laden F, Hart JE (2018) Ambient PM 2.5 air pollution exposure and hepatocellular carcinoma incidence in the United States. *Cancer Causes Control* 29(6):563–572
13. White AJ, Keller JP, Zhao S, Carroll R, Kaufman JD, Sandler DP (2019) Air pollution, clustering of particulate matter components, and breast cancer in the sister study: a US-wide cohort. *Environ Health Persp* 127(10):107002
14. Turner MC, Gracia-Lavedan E, Cirac M et al (2019) Ambient air pollution and incident bladder cancer risk: updated analysis of the Spanish bladder cancer study. *Int J Cancer* 145(4):894–900
15. Raaschou-Nielsen O, Pedersen M, Stafoggia M et al (2017) Outdoor air pollution and risk for kidney parenchyma cancer in 14 European cohorts. *Int J Cancer* 140(7):1528–1537
16. Wang H, Gao Z, Ren J et al (2019) An urban-rural and sex differences in cancer incidence and mortality and the relationship with PM_{2.5} exposure: an ecological study in the southeastern side of Hu line. *Chemosphere* 216:766–773
17. Ethan CJ, Mokoena KK, Yu Y et al (2020) Association between PM_{2.5} and mortality of stomach and colorectal cancer in Xi'an: a time-series study. *Environ Sci* 1:1–11
18. Wong CM, Tsang H, Lai HK et al (2016) Cancer mortality risks from long-term exposure to ambient fine particle. *Cancer Epidem Biomark* 25(5):839–845
19. Turner MC, Krewski D, Diver WR et al (2017) Ambient air pollution and cancer mortality in the Cancer Prevention Study II. *Environ Health Persp*. <https://doi.org/10.1007/s11356-020-08628-0>
20. Deng H, Eckel SP, Liu L, Lurmann FW, Cockburn MG, Gilliland FD (2017) Particulate matter air pollution and liver cancer survival. *Int J Cancer* 141(4):744–749
21. Wang Y, Li M, Wan X et al (2018) Spatiotemporal analysis of PM_{2.5} and pancreatic cancer mortality in China. *Environ Res* 164:132–139
22. DuPre N, Poole EM, Holmes MD et al (2019) Particulate matter and traffic-related exposures in relation to breast cancer survival. *Cancer Epidem Biomark* 28(4):751–759
23. Yeh HL, Hsu SW, Chang YC, Chan TC, Tsou HC, Chang YC, Chiang PH (2017) Spatial analysis of ambient PM_{2.5} exposure and bladder cancer mortality in Taiwan. *Int J Environ Res Public Health* 14(5):508
24. Kim SY, Bechle M, Hankey S, Sheppard L, Szpiro AA, Marshall JD (2020) Concentrations of criteria pollutants in the contiguous US, 1979–2015: role of prediction model parsimony in integrated empirical geographic regression. *PLoS ONE* 15(2):e0228535
25. National Center for Health Statistics (2015) 2014 Survey description, National Health Interview Survey (NHIS). Division of Health Interview Statistics. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NHIS/2014/srvydesc.pdf. Accessed 31 Apr 2018

26. Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. *Stat Med* 9:811–818
27. National Center for Health Statistics (2018) Underlying and multiple cause of death codes. National Center for Health Statistics. https://www.cdc.gov/nchs/data/datalinkage/underlying_and_multiple_cause_of_death_codes.pdf. Accessed 7 May 2020
28. Pun VC, Kazemiparkouhi F, Manjourides J, Suh HH (2017) Long-term PM_{2.5} exposure and respiratory, cancer, and cardiovascular mortality in older US adults. *Am J Epidemiol* 186(8):961–969
29. Krewski D, Burnett R, Goldberg M et al (2003) Overview of the reanalysis of the Harvard six cities study and American Cancer Society study of particulate air pollution and mortality. *J Toxicol* 66(16–19):1507–1552
30. Pope CA III, Coleman NC, Pond ZA, Burnett RT (2019) Fine particulate air pollution and human mortality: 25+ years of cohort studies. *Environ Res*. <https://doi.org/10.1016/j.envres.2019.108924>
31. Guo C, Chan TC, Teng YC et al (2020) Long-term exposure to ambient fine particles and gastrointestinal cancer mortality in Taiwan: a cohort study. *Environ Int* 138:105640
32. Iwai K, Mizuno S, Miyasaka Y, Mori T (2005) Correlation between suspended particles in the environmental air and causes of disease among inhabitants: cross-sectional studies using the vital statistics and air pollution data in Japan. *Environ Res* 99(1):106–117
33. Hu H, Dailey AB, Kan H, Xu X (2013) The effect of atmospheric particulate matter on survival of breast cancer among US females. *Breast Cancer Res Treatm* 139(1):217–226
34. Pan WC, Wu CD, Chen MJ, Huang YT, Chen CJ, Su HJ, Yang HI (2016) Fine particle pollution, alanine transaminase, and liver cancer: a Taiwanese prospective cohort study (REVEAL-HBV). *J Natl Cancer Inst*. <https://doi.org/10.1093/jnci/djv341>
35. Pedersen M, Andersen ZJ, Stafoggia M et al (2017) Ambient air pollution and primary liver cancer incidence in four European cohorts within the ESCAPE project. *Environ Res* 154:226–233
36. Reding KW, Young MT, Szpiro AA et al (2015) Breast cancer risk in relation to ambient air pollution exposure at residences in the Sister Study Cohort. *Cancer Epidem Biomark Prev* 24:1907–1909
37. Hart JE, Bertrand KA, DuPre N et al (2016) Long-term particulate matter exposures during adulthood and risk of breast cancer incidence in the Nurses' Health Study II Prospective Cohort. *Cancer Epidem Biomark Prev* 25:1274–1276
38. Andersen ZJ, Stafoggia M, Weinmayear G et al (2017) Long-term exposure to ambient air pollution and incidence of postmenopausal breast cancer in 15 European cohorts within the ESCAPE project. *Environ Health Perspect* 125(10):107005
39. Andersen ZJ, Ravnskjaer L, Andersen KK et al (2017) Long-term exposure to fine particulate matter and breast cancer incidence in the Danish Nurse Cohort Study. *Cancer Epidem Biomark Prev* 26(3):428–430
40. Bai L, Shin S, Burnett RT et al (2019) Exposure to ambient air pollution and the incidence of lung cancer and breast cancer in the Ontario Population Health and Environment Cohort (ONPHEC). *Int J Cancer* 146(9):2450–2459
41. Pedersen M, Stafoggia M, Weinmayear G et al (2018) Is there an association between ambient air pollution and bladder cancer incidence? Analysis of 15 European Cohorts. *Eur Urol Focus* 4(1):113–120
42. Carter BD, Abnet CC, Feskanich D et al (2015) Smoking and mortality—beyond established causes. *N Engl J Med* 372(7):631–640
43. Raaschou-Nielsen O, Andersen ZJ, Hvidberg M et al (2011) Air pollution from traffic and cancer incidence: a Danish cohort study. *Environ Health* 10(1):67
44. Ancona C, Badaloni C, Mataloni F et al (2015) Mortality and morbidity in a population exposed to multiple sources of air pollution: a retrospective cohort study using air dispersion models. *Environ Res* 137:467–474

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.